Unlocking New Life
from Proven Medicines
AIICAS was built on a simple but powerful idea: existing medicines may already hold answers to diseases we haven’t solved yet — we just haven’t had the tools to see it. Our decision engine uses AI to find new treatment strategies hidden in existing medical knowledge.
A broken system leaves medicines underutilised
Despite decades of research and billions in approved drugs, a fundamental gap exists between what we know and what patients receive.
Wasted Inventory
Effective medicines lose commercial focus once patents expire, sitting unused despite strong evidence for new uses.
Innovation Bias
The industry focuses overwhelmingly on developing new drugs rather than finding new uses for those already proven safe.
Inefficient Utilisation
Research insights are scattered across thousands of publications and databases, making systematic discovery impossible without AI.
The AIICAS Approach
We bridge the gap between existing medical knowledge and untapped treatment potential, using AI to do what no human team could do manually.
Scan. Advanced algorithms continuously analyse medical databases, patent records, and scientific literature.
Understand. We don’t just find patterns — we look for the biological mechanisms behind them, and why they arise.
Accelerate. Surface a shortlist of validated treatment opportunities, ready for research and clinical review.
From data to discovery in four steps
Our platform is built for precision. Each step is designed to narrow thousands of candidates into a shortlist of actionable insights.
Data Ingestion
We continuously pull from medical databases, clinical trial registries, scientific literature, and patent systems worldwide.
Pattern Detection
Our algorithms surface associations between existing medicines and disease mechanisms that are difficult to detect by hand.
Mechanistic Understanding
We go a step further — analysing the biology to understand why a connection exists, not just that it does.
Evidence-Based Output
Researchers receive ranked candidates with supporting evidence — ready for further development, clinical review, or partnership.
Built to understand disease over time
Beyond the results we’ve achieved in Parkinson’s, our decision engine is built to analyse complex disease trajectories — where a patient is along the disease path, which biological mechanisms appear to drive it forward, and how that understanding can sharpen target identification and drug development.
Designed for speed, precision, and impact
Faster Time to Treatment
Drug repurposing can compress development timelines from over a decade to just a few years, since safety profiles of existing medicines are already established.
Dramatically Lower Costs
Building on medicines that are already approved avoids much of the cost and risk of developing an entirely new drug from scratch.
Systematic, Not Serendipitous
Traditional drug repurposing has relied on chance observations. AIICAS makes it a systematic, scalable, and repeatable process driven by data.
Evidence-First Validation
Every candidate is backed by a traceable chain of scientific evidence — giving researchers and clinical partners confidence from day one.
Built for Partnerships
AIICAS is designed to collaborate — with academic institutions, biotech companies, clinical partners, and research hospitals around the world.
Existing medicines may already hold the answers to diseases we haven’t solved yet. We just haven’t had the tools to see it.
— The founders of AIICASA future where medicine is understood, not just observed
Disease detected earlier
Reading data and biology together to recognise the signals of disease sooner.
Treatment made more precise
Understanding the mechanisms behind disease so the right patients reach the right treatments.
Better decisions for research
Giving researchers and clinicians a stronger evidence base to act on with confidence.
Medicines with more to give.
We find them.
Whether you’re a researcher, clinician, or potential partner — we’d love to start a conversation.